medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2018, Number 6

<< Back Next >>

Ann Hepatol 2018; 17 (6)

Immunometabolic Effect of Cholesterol in Hepatitis C Infection: Implications in Clinical Management and Antiviral Therapy

González-Aldaco K, Torres-Reyes LA, Ojeda-Granados C, José-Ábrego A, Fierro NA, Román S

Language: English
References: 125
Page: 908-919
PDF size: 640.81 Kb.


ABSTRACT

Hepatitis C virus (HCV) is a lipid-enveloped virion particle that causes infection to the liver, and as part of its life cycle, it disrupts the host lipid metabolic machinery, particularly the cholesterol synthesis pathway. The innate immune response generated by liver resident immune cells is responsible for successful viral eradication. Unfortunately, most patients fail to eliminate HCV and progress to chronic infection. Chronic infection is associated with hepatic fat accumulation and inflammation that triggers fibrosis, cirrhosis, and eventually hepatocellular carcinoma. Despite that the current direct-acting antiviral agents have increased the cure rate of HCV infection, viral genotype and the host genetic background influence both the immune response and lipid metabolism. In this context, recent evidence has shown that cholesterol and its derivatives such as oxysterols might modulate and potentialize the hepatic innate immune response generated against HCV. The impairment of the HCV life cycle modulated by serum cholesterol could be relevant for the clinical management of HCV-infected patients before and after treatment. Alongside, cholesterol levels are modulated either by genetic variations in IL28B, ApoE, and LDLR or by dietary components. Indeed, some nutrients such as unsaturated fatty acids have demonstrated to be effective against HCV replication. Thus, cholesterol modifications may be considered as a new adjuvant strategy for HCV infection therapy by providing a biochemical tool that guides treatment decisions, an improved treatment response and favoring viral clearance. Herein, the mechanisms by which cholesterol contributes to the immune response against HCV infection and how genetic and environmental factors may affect this role are reviewed.


REFERENCES

  1. WHO. Hepatitis C. 2018. Available from: http://wwwwhoint/ news-room/fact-sheets/detail/hepatitis-c

  2. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444: 860-7.

  3. Schertzer JD, Steinberg GR. Immunometabolism: the interface of immune and metabolic responses in disease. Immunol Cell Biol 2014; 92: 303.

  4. Protzer U, Maini MK, Knolle PA. Living in the liver: hepatic infections. Nat Rev Immunol 2012; 12: 201-13.

  5. Popescu CI, Riva L, Vlaicu O, Farhat R, Rouille Y, Dubuisson J. Hepatitis C virus life cycle and lipid metabolism. Biology (Basel) 2014; 3: 892-921.

  6. Syed GH, Amako Y, Siddiqui A. Hepatitis C virus hijacks host lipid metabolism. Trends Endocrinol Metab 2010; 21: 33-40.

  7. Modaresi Esfeh J, Ansari-Gilani K. Steatosis and hepatitis C. Gastroenterol Rep (Oxf) 2016; 4: 24-9.

  8. Dyal HK, Aguilar M, Bhuket T, Liu B, Holt EW, Torres S, Cheung, R, et al. Concurrent Obesity, Diabetes, and Steatosis Increase Risk of Advanced Fibrosis Among HCV Patients: A Systematic Review. Dig Dis Sci 2015; 60: 2813-24.

  9. Vescovo T, Refolo G, Vitagliano G, Fimia GM, Piacentini M. Molecular mechanisms of hepatitis C virus-induced hepatocellular carcinoma. Clin Microbiol Infect 2016; 22: 853-61.

  10. Horner SM. Activation and evasion of antiviral innate immunity by hepatitis C virus. J Mol Biol 2014; 426: 1198-209.

  11. Li K, Lemon SM. Innate immune responses in hepatitis C virus infection. Semin Immunopathol 2013; 35: 53-72.

  12. Grunfeld C, Feingold KR. Tumor necrosis factor, interleukin, and interferon induced changes in lipid metabolism as part of host defense. Proc Soc Exp Biol Med 1992; 200: 224-7.

  13. Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol 2014; 61(1 Suppl.): S58-S68.

  14. Mengshol JA, Golden-Mason L, Rosen HR. Mechanisms of Disease: HCV-induced liver injury. Nat Clin Pract Gastroenterol Hepatol 2007; 4: 622-34.

  15. Cacoub P, Si Ahmed SN, Ferfar Y, Pol S, Thabut D, Hezode C, Alric L, et al. Long-Term Efficacy of Interferon-Free Antiviral Treatment Regimens in Patients With Hepatitis C Virus- Associated Cryoglobulinemia Vasculitis. Clin Gastroenterol Hepatol 2018.

  16. Rivero-Juarez A, Brieva T, Frias M, Rivero A. Pharmacodynamic and pharmacokinetic evaluation of the combination of daclatasvir/sofosbuvir/ribavirin in the treatment of chronic hepatitis C. Expert Opin Drug Metab Toxicol 2018: 1-10.

  17. Flamm S, Reddy KR, Zadeikis N, Hassanein T, Bacon BR, Maieron A, Zeuzem S, et al. Efficacy and Pharmacokinetics of Glecaprevir and Pibrentasvir With Concurrent Use of Acid-Reducing Agents in Patients With Chronic HCV Infection. Clin Gastroenterol Hepatol 2018.

  18. Das D, Pandya M. Recent Advancement of Direct-acting Antiviral Agents (DAAs) in Hepatitis C Therapy. Mini Rev Med Chem 2018; 18: 584-96.

  19. Rein DB, Wittenborn JS, Smith BD, Liffmann DK, Ward JW. The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus. Clin Infect Dis 2015; 61: 157-68.

  20. Panduro A, Roman S. Need of righteous attitudes towards eradication of hepatitis C virus infection in Latin America. World J Gastroenterol 2016; 22: 5137-42.

  21. Panduro A, Escobedo Meléndez G, Fierro NA, Ruiz Madrigal B, Zepeda-Carrillo EA, Román S. Epidemiology of viral hepatitis in Mexico. Salud Publica Mex 2011; 53(Suppl. 1): S37- S45. Review. [Spanish].

  22. Panduro A, Roman S, Khan A, Tanaka Y, Kurbanov F, Martinez- Lopez E, Campollo O, et al. Molecular epidemiology of hepatitis C virus genotypes in west Mexico. Virus Res 2010; 151: 19-25.

  23. Sun D, Dai M, Shen S, Li C, Yan X. Analysis of Naturally Occurring Resistance-Associated Variants to NS3/4A Protein Inhibitors, NS5A Protein Inhibitors, and NS5B Polymerase Inhibitors in Patients With Chronic Hepatitis C. Gene Expr 2018; 18: 63-9.

  24. Holmes JA, Congiu M, Bonanzinga S, Sandhu MK, Kia YH, Bell SJ, Nguyen T, et al. The relationships between IFNL4 genotype, intrahepatic interferon-stimulated gene expression and interferon treatment response differs in HCV-1 compared with HCV-3. Aliment Pharmacol Ther 2015; 42: 296-306.

  25. Pezacki JP, Sagan SM, Tonary AM, Rouleau Y, Belanger S, Supekova L, Su AI. Transcriptional profiling of the effects of 25-hydroxycholesterol on human hepatocyte metabolism and the antiviral state it conveys against the hepatitis C virus. BMC Chem Biol 2009; 9: 2.

  26. Su AI, Pezacki JP, Wodicka L, Brideau AD, Supekova L, Thimme R, Wieland S, et al. Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci USA 2002; 99: 15669-74.

  27. Fierro NA, Gonzalez-Aldaco K, Roman S, Panduro A. The immune system and viral hepatitis. In: Muriel P. Liver pathophysiology: therapies & antioxidants. Waltham, MA: Elsevier; 2017, pp. 129-39.

  28. Singaravelu R, O’Hara S, Jones DM, Chen R, Taylor NG, Srinivasan P, Quan C, et al. MicroRNAs regulate the immunometabolic response to viral infection in the liver. Nat Chem Biol 2015; 11: 988-93.

  29. Fierro NA, Gonzalez-Aldaco K, Torres-Valadez R, Martinez- Lopez E, Roman S, Panduro A. Immunologic, metabolic and genetic factors in hepatitis C virus infection. World J Gastroenterol 2014; 20: 3443-56.

  30. Suzuki T. Morphogenesis of Infectious Hepatitis C Virus Particles. Frontiers in Microbiology 2012; 3.

  31. Nguyen P, Leray V, Diez M, Serisier S, Le Bloc’h J, Siliart B, Dumon H. Liver lipid metabolism. J Anim Physiol Anim Nutr (Berl) 2008; 92: 272-83.

  32. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343: 425-30.

  33. Syed GH, Tang H, Khan M, Hassanein T, Liu J, Siddiqui A. Hepatitis C virus stimulates low-density lipoprotein receptor expression to facilitate viral propagation. J Virol 2014; 88: 2519-29.

  34. Gabor KA, Fessler MB. Roles of the Mevalonate Pathway and Cholesterol Trafficking in Pulmonary Host Defense. Curr Mol Pharmacol 2017; 10: 27-45.

  35. Syed GH, Khan M, Yang S, Siddiqui A. Hepatitis C Virus Lipoviroparticles Assemble in the Endoplasmic Reticulum (ER) and Bud off from the ER to the Golgi Compartment in COPII Vesicles. J Virol 2017; 91.

  36. Grove J, Nielsen S, Zhong J, Bassendine MF, Drummer HE, Balfe P, McKeating JA. Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies. J Virol 2008; 82: 12020-9.

  37. Cheng JJ, Li JR, Huang MH, Ma LL, Wu ZY, Jiang CC, Li WJ, et al. CD36 is a co-receptor for hepatitis C virus E1 protein attachment. Scientific reports 2016; 6: 21808.

  38. Fukuhara T, Matsuura Y. Roles of lipoprotein and apolipoprotein in HCV infection. Uirusu 2015; 65: 269-76.

  39. Felmlee DJ, Hafirassou ML, Lefevre M, Baumert TF, Schuster C. Hepatitis C virus, cholesterol and lipoproteins—impact for the viral life cycle and pathogenesis of liver disease. Viruses 2013; 5: 1292-324.

  40. Tong Y, Zhu Y, Xia X, Liu Y, Feng Y, Hua X, Chen Z, et al. Tupaia CD81, SR-BI, claudin-1, and occludin support hepatitis C virus infection. J Virol 2011; 85: 2793-802.

  41. Feneant L, Levy S, Cocquerel L. CD81 and hepatitis C virus (HCV) infection. Viruses 2014; 6: 535-72.

  42. McRae S, Iqbal J, Sarkar-Dutta M, Lane S, Nagaraj A, Ali N, Waris G. The Hepatitis C Virus-induced NLRP3 Inflammasome Activates the Sterol Regulatory Element-binding Protein (SREBP) and Regulates Lipid Metabolism. J Biol Chem 2016; 291: 3254-67.

  43. Huang H, Sun F, Owen DM, Li W, Chen Y, Gale M, Jr., Ye J. Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. Proc Natl Acad Sci USA 2007; 104: 5848-53.

  44. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002; 109: 1125-31.

  45. Shimano H. SREBPs: physiology and pathophysiology of the SREBP family. FEBS J 2009; 276: 616-21.

  46. Silbernagel G, Kovarova M, Cegan A, Machann J, Schick F, Lehmann R, Haring HU, et al. High hepatic SCD1 activity is associated with low liver fat content in healthy subjects under a lipogenic diet. J Clin Endocrinol Metab 2012; 97: E2288-E2292.

  47. Lyn RK, Singaravelu R, Kargman S, O’Hara S, Chan H, Oballa R, Huang Z, et al. Stearoyl-CoA desaturase inhibition blocks formation of hepatitis C virus-induced specialized membranes. Sci Rep 2014; 4: 4549.

  48. Chao TC, Su WC, Huang JY, Chen YC, Jeng KS, Wang HD, Lai MM. Proline-serine-threonine phosphatase-interacting protein 2 (PSTPIP2), a host membrane-deforming protein, is critical for membranous web formation in hepatitis C virus replication. J Virol 2012; 86: 1739-49.

  49. Romero-Brey I, Merz A, Chiramel A, Lee JY, Chlanda P, Haselman U, Santarella-Mellwig, R, et al. Three-dimensional architecture and biogenesis of membrane structures associated with hepatitis C virus replication. PLoS Pathog 2012; 8: e1003056.

  50. Fabris C, Federico E, Soardo G, Falleti E, Pirisi M. Blood lipids of patients with chronic hepatitis: differences related to viral etiology. Clin Chim Acta 1997; 261: 159-65.

  51. Hui JM, Kench J, Farrell GC, Lin R, Samarasinghe D, Liddle C, Byth K, et al. Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection. J Gastroenterol Hepatol 2002; 17: 873-81.

  52. Tsalikis J, Croitoru DO, Philpott DJ, Girardin SE. Nutrient sensing and metabolic stress pathways in innate immunity. Cell Microbiol 2013; 15: 1632-41.

  53. Xiang Y, Tang JJ, Tao W, Cao X, Song BL, Zhong J. Identification of Cholesterol 25-Hydroxylase as a Novel Host Restriction Factor and a Part of the Primary Innate Immune Responses against Hepatitis C Virus Infection. J Virol 2015; 89: 6805-16.

  54. Fierro NA, Gonzalez-Aldaco K, Torres-Valadez R, Trujillo-Trujillo ME, Roman S, Trujillo-Ochoa JL, Panduro, A. Spontaneous hepatitis C viral clearance and hepatitis C chronic infection are associated with distinct cytokine profiles in Mexican patients. Mem Inst Oswaldo Cruz 2015; 110: 267-71.

  55. Simon A. Cholesterol metabolism and immunity. N Engl J Med 2014; 371: 1933-5.

  56. Ogawa E, Furusyo N, Kajiwara E, Nomura H, Dohmen K, Takahashi K, et al. Influence of low-density lipoprotein cholesterol on virological response to telaprevir-based triple therapy for chronic HCV genotype 1b infection. Antiviral Res 2014; 104: 102-9.

  57. Tall AR, Yvan-Charvet L. Cholesterol, inflammation and innate immunity. Nat Rev Immunol 2015; 15: 104-16.

  58. Machida K, Cheng KT, Sung VM, Levine AM, Foung S, Lai MM. Hepatitis C virus induces toll-like receptor 4 expression, leading to enhanced production of beta interferon and interleukin- 6. J Virol 2006; 80: 866-74.

  59. Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol 2014; 6: a016295.

  60. Huang M, Jiang JD, Peng Z. Recent advances in the anti- HCV mechanisms of interferon. Acta Pharm Sin B 2014; 4: 241-7.

  61. Mackenzie JM, Khromykh AA, Parton RG. Cholesterol manipulation by West Nile virus perturbs the cellular immune response. Cell Host Microbe 2007; 2: 229-39.

  62. Townsend K, Meissner EG, Sidharthan S, Sampson M, Remaley AT, Tang L, Kohli A, et al. Interferon-Free Treatment of Hepatitis C Virus in HIV/Hepatitis C Virus-Coinfected Subjects Results in Increased Serum Low-Density Lipoprotein Concentration. AIDS Res Hum Retroviruses 2016; 32: 456-62.

  63. Sheridan DA, Bridge SH, Felmlee DJ, Crossey MM, Thomas HC, Taylor-Robinson SD, Toms GL, et al. Apolipoprotein-E and hepatitis C lipoviral particles in genotype 1 infection: evidence for an association with interferon sensitivity. J Hepatol 2012; 57: 32-8.

  64. Grebely J, Feld JJ, Applegate T, Matthews GV, Hellard M, Sherker A, Petoumenos K, et al. Plasma interferon-gammainducible protein-10 (IP-10) levels during acute hepatitis C virus infection. Hepatology 2013; 57: 2124-34.

  65. Owen DM, Huang H, Ye J, Gale M, Jr. Apolipoprotein E on hepatitis C virion facilitates infection through interaction with low-density lipoprotein receptor. Virology 2009; 394: 99-108.

  66. Westhaus S, Bankwitz D, Ernst S, Rohrmann K, Wappler I, Agne C, Luchtefeld M, et al. Characterization of the inhibition of hepatitis C virus entry by in vitro-generated and patientderived oxidized low-density lipoprotein. Hepatology 2013; 57: 1716-24.

  67. von Hahn T, Lindenbach BD, Boullier A, Quehenberger O, Paulson M, Rice CM, McKeating JA. Oxidized low-density lipoprotein inhibits hepatitis C virus cell entry in human hepatoma cells. Hepatology 2006; 43: 932-42.

  68. Nakhjavani M, Mashayekh A, Khalilzadeh O, Asgarani F, Morteza A, Omidi M, Froutan H. Oxidized low-density lipoprotein is associated with viral load and disease activity in patients with chronic hepatitis C. Clin Res Hepatol Gastroenterol 2011; 35: 111-6.

  69. Solbach P, Westhaus S, Deest M, Herrmann E, Berg T, Manns MP, Ciesek S. Oxidized Low-Density Lipoprotein Is a Novel Predictor of Interferon Responsiveness in Chronic Hepatitis C Infection. Cell Mol Gastroenterol Hepatol 2015; 1: 285-94 e1.

  70. Howell KW, Meng X, Fullerton DA, Jin C, Reece TB, Cleveland JC, Jr. Toll-like receptor 4 mediates oxidized LDL-induced macrophage differentiation to foam cells. J Surg Res 2011; 171: e27-e31.

  71. Russell DW. Oxysterol biosynthetic enzymes. Biochim Biophys Acta 2000; 1529: 126-35.

  72. Park K, Scott AL. Cholesterol 25-hydroxylase production by dendritic cells and macrophages is regulated by type I interferons. J Leukoc Biol 2010; 88: 1081-7.

  73. Lund EG, Kerr TA, Sakai J, Li WP, Russell DW. cDNA cloning of mouse and human cholesterol 25-hydroxylases, polytopic membrane proteins that synthesize a potent oxysterol regulator of lipid metabolism. J Biol Chem 1998; 273: 34316-27.

  74. Janowski BA, Willy PJ, Devi TR, Falck JR, Mangelsdorf DJ. An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature 1996; 383: 728-31.

  75. Radhakrishnan A, Ikeda Y, Kwon HJ, Brown MS, Goldstein JL. Sterol-regulated transport of SREBPs from endoplasmic reticulum to Golgi: oxysterols block transport by binding to Insig. Proc Natl Acad Sci USA 2007; 104: 6511-8.

  76. Chen Y, Wang S, Yi Z, Tian H, Aliyari R, Li Y, Chen G, et al. Interferon-inducible cholesterol-25-hydroxylase inhibits hepatitis C virus replication via distinct mechanisms. Sci Rep 2014; 4: 7242.

  77. Wu JM, Skill NJ, Maluccio MA. Evidence of aberrant lipid metabolism in hepatitis C and hepatocellular carcinoma. HPB (Oxford) 2010; 12: 625-36.

  78. Ramcharran D, Wahed AS, Conjeevaram HS, Evans RW, Wang T, Belle SH, Yee LJ, et al. Associations between serum lipids and hepatitis C antiviral treatment efficacy. Hepatology 2010; 52: 854-63.

  79. Hashimoto S, Yatsuhashi H, Abiru S, Yamasaki K, Komori A, Nagaoka S, Saeki A, et al. Rapid Increase in Serum Low- Density Lipoprotein Cholesterol Concentration during Hepatitis C Interferon-Free Treatment. PLoS One 2016; 11: e0163644.

  80. Economou M, Milionis H, Filis S, Baltayiannis G, Christou L, Elisaf M, Tsianos E. Baseline cholesterol is associated with the response to antiviral therapy in chronic hepatitis C. J Gastroenterol Hepatol 2008; 23: 586-91.

  81. Cavalcante LN, Lyra AC. Predictive factors associated with hepatitis C antiviral therapy response. World J Hepatol 2015; 7: 1617-31.

  82. Clement ME, Park LP, Navar AM, Okeke NL, Pencina MJ, Douglas PS, Naggie S. Statin Utilization and Recommendations Among HIV- and HCV-infected Veterans: A Cohort Study. Clin Infect Dis 2016; 63: 407-13.

  83. Illingworth DR, Bacon S. Hypolipidemic effects of HMG-CoA reductase inhibitors in patients with hypercholesterolemia. Am J Cardiol 1987; 60: 33G-42G.

  84. Ikeda M, Abe K, Yamada M, Dansako H, Naka K, Kato N. Different anti-HCV profiles of statins and their potential for combination therapy with interferon. Hepatology 2006; 44: 117-25.

  85. Blanchet M, Le QT, Seidah NG, Labonte P. Statins can exert dual, concentration dependent effects on HCV entry in vitro. Antiviral Res 2016; 128: 43-8.

  86. Evans MJ, von Hahn T, Tscherne DM, Syder AJ, Panis M, Wolk B, Hatziioannou T, et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 2007; 446: 801-5.

  87. Sugimoto K, Stadanlick J, Ikeda F, Brensinger C, Furth EE, Alter HJ, Chang KM. Influence of ethnicity in the outcome of hepatitis C virus infection and cellular immune response. Hepatology 2003; 37: 590-9.

  88. Su F, Green PK, Berry K, Ioannou GN. The association between race/ethnicity and the effectiveness of direct antiviral agents for hepatitis C virus infection. Hepatology 2017; 65: 426-38.

  89. Gonzalez-Aldaco K, Rebello Pinho JO, Panduro A, Martinez- Lopez E, Gleyzer K, Fierro N, Roman S. High Prevalence of ITPA Alleles Associated with Ribavirin-Induced Hemolytic Anemia Among Mexican Population. Ann Hepatol 2017; 16: 221-9.

  90. Coppola N, Pisaturo M, Sagnelli C, Onorato L, Sagnelli E. Role of genetic polymorphisms in hepatitis C virus chronic infection. World J Clin Cases 2015; 3: 807-22.

  91. Roman S, Panduro A. Genomic medicine in gastroenterology: A new approach or a new specialty? World J Gastroenterol 2015; 21: 8227-37.

  92. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, Langer JA, et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003; 4: 69-77.

  93. O’Connor KS, George J, Booth D, Ahlenstiel G. Dendritic cells in hepatitis C virus infection: key players in the IFNL3-genotype response. World J Gastroenterol 2014; 20: 17830-8.

  94. Donnelly RP, Dickensheets H, O’Brien TR. Interferon-lambda and therapy for chronic hepatitis C virus infection. Trends Immunol 2011; 32: 443-50.

  95. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.

  96. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O’Huigin C, Kidd J, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.

  97. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-9.

  98. Calisti G, Tavares A, Macartney MJ, McCormick A, Labbett W, Jacobs M, Dusheiko G, et al. IL28B genotype predicts response to chronic hepatitis C triple therapy with telaprevir or boceprevir in treatment naive and treatment-experienced patients other than prior partial- and null-responders. Springerplus 2015; 4: 357.

  99. Gonzalez-Aldaco K, Rebello Pinho JR, Roman S, Gleyzer K, Fierro NA, Oyakawa L, Ramos-Lopez O, et al. Association with Spontaneous Hepatitis C Viral Clearance and Genetic Differentiation of IL28B/IFNL4 Haplotypes in Populations from Mexico. PLoS One 2016; 11: e0146258.

  100. 100.Lee MH, Yang HI, Lu SN, Lin YJ, Jen CL, Wong KH, Chan SY, et al. Polymorphisms near the IFNL3 Gene Associated with HCV RNA Spontaneous Clearance and Hepatocellular Carcinoma Risk. Sci Rep 2015; 5: 17030.

  101. 101.Carapito R, Poustchi H, Kwemou M, Untrau M, Sharifi AH, Merat S, Haj-Sheykholeslami A, et al. Polymorphisms in EGFR and IL28B are associated with spontaneous clearance in an HCV-infected Iranian population. Genes Immun 2015; 16: 514-8.

  102. 102.Li JH, Lao XQ, Tillmann HL, Rowell J, Patel K, Thompson A, Suchindran S, et al. Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. Hepatology 2010; 51: 1904-11.

  103. 103.Beinhardt S, Aberle JH, Strasser M, Dulic-Lakovic E, Maieron A, Kreil A, Rutter K, et al. Serum level of IP-10 increases predictive value of IL28B polymorphisms for spontaneous clearance of acute HCV infection. Gastroenterology 2012; 142: 78-85 e2.

  104. 104.Phillips MC. Apolipoprotein E isoforms and lipoprotein metabolism. IUBMB life 2014; 66: 616-23.

  105. 105.Benga WJ, Krieger SE, Dimitrova M, Zeisel MB, Parnot M, Lupberger J, Hildt E, et al. Apolipoprotein E interacts with hepatitis C virus nonstructural protein 5A and determines assembly of infectious particles. Hepatology 2010; 51: 43-53.

  106. 106.Merz A, Long G, Hiet MS, Brugger B, Chlanda P, Andre P, Wieland F, et al. Biochemical and morphological properties of hepatitis C virus particles and determination of their lipidome. J Biol Chem 2011; 286: 3018-32.

  107. 107.Mahley RW, Rall SC, Jr. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet 2000; 1: 507-37.

  108. 108.Roman S, Ojeda-Granados C, Ramos-Lopez O, Panduro A. Genome-based nutrition: An intervention strategy for the prevention and treatment of obesity and nonalcoholic steatohepatitis. World J Gastroenterol 2015; 21: 3449-61.

  109. 109.Price DA, Bassendine MF, Norris SM, Golding C, Toms GL, Schmid ML, Morris CM, et al. Apolipoprotein epsilon3 allele is associated with persistent hepatitis C virus infection. Gut 2006; 55: 715-8.

  110. 110.Wozniak MA, Itzhaki RF, Faragher EB, James MW, Ryder SD, Irving WL. Apolipoprotein E-epsilon 4 protects against severe liver disease caused by hepatitis C virus. Hepatology 2002; 36: 456-63.

  111. 111.Lye SH, Chahil JK, Bagali P, Alex L, Vadivelu J, Ahmad WA, Chan SP, et al. Genetic polymorphisms in LDLR, APOB, PCSK9 and other lipid related genes associated with familial hypercholesterolemia in Malaysia. PLoS One 2013; 8: e60729.

  112. 112.Mattevi VS, Coimbra CE, Jr. Santos RV, Salzano FM, Hutz MH. Association of the low-density lipoprotein receptor gene with obesity in Native American populations. Hum Genet 2000; 106: 546-52.

  113. 113.Caruz A, Neukam K, Rivero-Juarez A, Herrero R, Real LM, Camacho A, Barreiro P, et al. Association of low-density lipoprotein receptor genotypes with hepatitis C viral load. Genes Immun 2014; 15: 16-24.

  114. 114.Pineda JA, Caruz A, Di Lello FA, Camacho A, Mesa P, Neukam K, Rivero-juarez A, et al. Low-density lipoprotein receptor genotyping enhances the predictive value of IL28B genotype in HIV/hepatitis C virus-coinfected patients. AIDS 2011; 25: 1415-20.

  115. 115.Schectman G, Kaul S, Mueller RA, Borden EC, Kissebah AH. The effect of interferon on the metabolism of LDLs. Arterioscler Thromb 1992; 12: 1053-62.

  116. 116.Albecka A, Belouzard S, Op de Beeck A, Descamps V, Goueslain L, Bertrand-Michel J, Terce F, et al. Role of low-density lipoprotein receptor in the hepatitis C virus life cycle. Hepatology 2012; 55: 998-1007.

  117. 117.Leu GZ, Lin TY, Hsu JT. Anti-HCV activities of selective polyunsaturated fatty acids. Biochem Biophys Res Commun 2004; 318: 275-80.

  118. 118.Poli G, Biasi F, Leonarduzzi G. Oxysterols in the pathogenesis of major chronic diseases. Redox biology 2013; 1: 125-30.

  119. 119.Maggio R, Viscomi C, Andreozzi P, D’Ettorre G, Viscogliosi G, Barbaro B, Gori M, et al. Normocaloric low cholesterol diet modulates Th17/Treg balance in patients with chronic hepatitis C virus infection. PLoS One 2014; 9: e112346.

  120. 120.Klop B, Elte JW, Cabezas MC. Dyslipidemia in obesity: mechanisms and potential targets. Nutrients 2013; 5: 1218-40.

  121. 121.Ojeda-Granados C, Panduro A, Gonzalez-Aldaco K, Sepulveda-Villegas M, Rivera-Iniguez I, Roman S. Tailoring Nutritional Advice for Mexicans Based on Prevalence Profiles of Diet-Related Adaptive Gene Polymorphisms. J Pers Med 2017; 7.

  122. 122.Fuentes R, Uusitalo T, Puska P, Tuomilehto J, Nissinen A. Blood cholesterol level and prevalence of hypercholesterolaemia in developing countries: a review of populationbased studies carried out from 1979 to 2002. Eur J Cardiovasc Prev Rehabil 2003; 10: 411-9.

  123. 123.Kapadia SB, Chisari FV. Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc Natl Acad Sci USA 2005; 102: 2561-6.

  124. 124.Yano M, Ikeda M, Abe K, Dansako H, Ohkoshi S, Aoyagi Y, Kato N. Comprehensive analysis of the effects of ordinary nutrients on hepatitis C virus RNA replication in cell culture. Antimicrob Agents Chemother 2007; 51: 2016-27.

  125. 125.Govea-Salas M, Rivas-Estilla AM, Rodriguez-Herrera R, Lozano- Sepulveda SA, Aguilar-Gonzalez CN, Zugasti-Cruz A, Salas-Villalobos TB, et al. Gallic acid decreases hepatitis C virus expression through its antioxidant capacity. Exp Ther Med 2016; 11: 619-24.




2020     |     www.medigraphic.com